Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

Abroad (travel likely)RecruitingPHASE3

Conditions

Apathy · Schizophrenia · Schizophrenia; Psychosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

LSU Health Shreveport, Shreveport, Louisiana, United States
Contact: Study coordinator (Stephanie Saunders, MA, CCRC) · stephanie.saunders@lsuhs.edu · 318-675-7065
Contact: Study coordinator (Shawn McNeil, MD) · shawn.mcneil@lsuhs.edu · 318-675-7065
Contact: Principal Investigator (Shawn McNeil, MD)

Study leads

Shawn McNeil, MD
Principal Investigator
LSU Health Shreveport

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

In Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy.

Apathy

Abroad (travel likely)RecruitingPHASE3

Bordeaux, France

Accelerated rTMS vs. Sham for Stroke Apathy

Apathy · Stroke · Stroke Sequelae

Abroad (travel likely)RecruitingPHASE1, PHASE2

Charleston, United States

Robotic Technologies for APATHy in Dementia: a Randomised Controlled Trial (RAPHAel)

Apathy · Apathy in Dementia

Abroad (travel likely)Recruiting

Milan, Italy · Modena, Italy

rTMS for Apathy Clinical Trial

Alzheimer Disease · Apathy in Dementia · Dementia

Abroad (travel likely)Recruiting

Toronto, Canada